CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

NCT05931276 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

2540

Enrollment

FED

Sponsor class

Conditions

End-Stage Kidney Disease
End-Stage Renal Disease

Interventions

DRUG: Metoprolol Succinate
DRUG: Carvedilol

Sponsor

VA Office of Research and Development